Delivery Order SPE2DB20D3101-SPE2DB25FRSS1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a $1,729.00 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract executed on August 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention, representing the type of specialty...
- The Defense Logistics Agency awarded a delivery order valued at $3,116.22 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Emgality 120 mg/ml in pen format. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under an open competition process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. Emgality is a monoclonal antibody treatment...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Emgality 120 mg/ml pen injectors, with a ceiling value of $1,554.86. This firm fixed-price delivery order is scheduled for completion by July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made without a set-aside designation, indicating open competition. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,074.80 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitive award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,729.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $3,458.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injections on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside award was competitively procured and will be performed at the contractor's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplied the product...
- The Defense Logistics Agency awarded a delivery order valued at $1,990.63 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as the...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $3,034.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This firm fixed-price, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,074.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen/ml, a pharmaceutical product used in migraine treatment. This non-competitive, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRSS1Delivery Order
The Defense Logistics Agency (DLA) awarded a $1,355.21 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injections on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The prime contractor, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare procurement. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention and treatment, demonstrating the DLA's ongoing procurement of specialty pharmaceutical products to support military medical needs. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999.00 DLA Troop Support Medical IDC (SPE2DX) vehicle, which extends through December 2026 and enables the company to supply a broad range of pharmaceutical products and medical supplies globally to support military healthcare programs. The company's contract portfolio with DLA demonstrates consistent capability in fulfilling diverse pharmaceutical procurement requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. The delivery to the Conshohocken, Pennsylvania location reflects the company's established distribution infrastructure and ability to meet federal medical supply chain demands through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/15/25 |